Skip to main content

$0.860 0.010 (1.18%)

High

$0.88

Low

$0.86

Trades

19

Turnover

$55,369

Volume

64,140
30 June 2023 at 3:08pm
Register to track PIQ and receive email alerts.
Subject
PIQ Ann: Change of Registry Address

PIQ Ann: Proteomics secures major pharmacokinetic testing contract

PIQ Ann: Proteomics receives $1.2 million in R&D tax incentive

PIQ Ann: Notification regarding unquoted securities - PIQ

PIQ Ann: Issue of Equity Incentives to Employees

PIQ Ann: Final Director's Interest Notice

PIQ Ann: Results of Annual General Meeting

PIQ Ann: AGM Chairman's Address and Investor Presentation

PIQ Ann: FDA advises regulatory pathway for PromarkerD in US

PIQ Ann: PromarkerD distribution network expands to Britain

PIQ Ann: Initial Directors' Interest Notices

PIQ Ann: Proposed issue of securities - PIQ

PIQ Ann: Director appointments

PIQ Ann: PromarkerD outperforms standard of care tests for DKD

PIQ Ann: Change of Directors' Interest Notices

PIQ Ann: Exercise of Director Options

PIQ Ann: Application for quotation of securities - PIQ

PIQ Ann: Proteomics awarded $100,000 manufacturing funding

PIQ Ann: Jobkeeper Payments Notification

PIQ Ann: September 2021 Quarterly Activities Report and Appendix 4C

PIQ Ann: Notice of Annual General Meeting/Proxy Form

PIQ Ann: Proteomics Chairman Terry Sweet to retire at 2021 AGM

PIQ Ann: Clinical utility study shows benefit of PromarkerD testing

PIQ Ann: Annual Report to shareholders

PIQ Ann: Preliminary Final Report

PIQ Ann: Corporate Governance Statement and Appendix 4G

PIQ Ann: Proteomics contracts Biotem to manufacture PromarkerD kits

PIQ Ann: Conference presentation - Australasian Diabetes Congress 202

PIQ Ann: Proteomics to collaborate to validate test for endometriosis

PIQ Ann: Application for quotation of securities - PIQ

PIQ Ann: Exercise of Options and Secondary Trading Notice

PIQ Ann: June 2021 Quarterly Activities Report and Appendix 4C

PIQ Ann: Manufacturing update and clarification of Abcam engagement

PIQ Ann: Proteomics engages Abcam to manufacture PromarkerD reagents

PIQ Ann: Notification regarding unquoted securities - PIQ

PIQ Ann: Issue of Equity Incentives to Key Management Personnel

PIQ Ann: Investor Presentation - non-deal roadshow

PIQ Ann: Study shows diabetes drug improves PromarkerD risk scores

PIQ Ann: Trading Halt

PIQ Ann: Pause in Trading

PIQ Ann: Reinstatement to Official Quotation

PIQ Ann: Update on study presented at ADA Conference

PIQ Ann: Request for extension of voluntary suspension

PIQ Ann: Suspension from Official Quotation

PIQ Ann: Trading Halt

PIQ Ann: Pause in Trading

PIQ Ann: Modelling shows PromarkerD could save US payers $384 billion

PIQ Ann: Proteomics bolsters executive team - CCO and CFO appointed

PIQ Ann: Proteomics secures major analytical services contract

PIQ Ann: Major economic health benefit demonstrated for PromarkerD

Register to track PIQ and receive email alerts.

Similar Companies

ADO
BPH
CTE
GSS
GTG
MEM
OSL
PAL